Clinical trials: Glanzmann Thrombasthenia
Glanzmann Thrombasthenia
Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study
Glanzmann thrombasthenia is a rare genetic disorder caused by the absence or the dysfunction of the main receptor present on the surface of platelets, integrin αIIbβ3 or GPIIb-IIIa.
- Trial name
- GLAT (NCT06234813)
- Testing
- Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen, : PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM, Thrombin Generation Assay (TGA) in PRP using TF trigger
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Glanzmann Thrombasthenia
The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
Blood contains red blood cells, white blood cells, and platelets, as well as a fluid portion termed plasma. We primarily study blood platelets, but sometimes we also analyze the blood of patients with red blood cell disorders…
- Trial name
- NCT00230165
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Rockefeller University